301 related articles for article (PubMed ID: 25194287)
1. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Felker GM; Ahmad T; Anstrom KJ; Adams KF; Cooper LS; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Leifer ES; Mark DB; Desvigne-Nickens P; Paynter G; Piña IL; Whellan DJ; O'Connor CM
JACC Heart Fail; 2014 Oct; 2(5):457-65. PubMed ID: 25194287
[TBL] [Abstract][Full Text] [Related]
2. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
4. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
[TBL] [Abstract][Full Text] [Related]
8. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
[TBL] [Abstract][Full Text] [Related]
9. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
[TBL] [Abstract][Full Text] [Related]
10. Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients.
Stienen S; Salah K; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Tijssen JP; Pinto YM; Kok WE
JACC Heart Fail; 2016 Sep; 4(9):736-45. PubMed ID: 27395353
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
12. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
[TBL] [Abstract][Full Text] [Related]
14. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
15. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.
Núñez J; Llàcer P; Bertomeu-González V; Bosch MJ; Merlos P; García-Blas S; Montagud V; Bodí V; Bertomeu-Martínez V; Pedrosa V; Mendizábal A; Cordero A; Gallego J; Palau P; Miñana G; Santas E; Morell S; Llàcer A; Chorro FJ; Sanchis J; Fácila L;
JACC Heart Fail; 2016 Nov; 4(11):833-843. PubMed ID: 27522630
[TBL] [Abstract][Full Text] [Related]
16. Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial.
Parcha V; Patel N; Kalra R; Suri SS; Arora G; Wang TJ; Arora P
J Am Heart Assoc; 2021 Apr; 10(7):e018689. PubMed ID: 33754794
[TBL] [Abstract][Full Text] [Related]
17. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF.
Daubert MA; Adams K; Yow E; Barnhart HX; Douglas PS; Rimmer S; Norris C; Cooper L; Leifer E; Desvigne-Nickens P; Anstrom K; Fiuzat M; Ezekowitz J; Mark DB; O'Connor CM; Januzzi J; Felker GM
JACC Heart Fail; 2019 Feb; 7(2):158-168. PubMed ID: 30611722
[TBL] [Abstract][Full Text] [Related]
18. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
[TBL] [Abstract][Full Text] [Related]
19. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
20. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.
Huelsmann M; Neuhold S; Resl M; Strunk G; Brath H; Francesconi C; Adlbrecht C; Prager R; Luger A; Pacher R; Clodi M
J Am Coll Cardiol; 2013 Oct; 62(15):1365-72. PubMed ID: 23810874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]